Bausch + Lomb was valued at $6.48 billion in the company’s U.S. market debut on May 6 as the eye-care company’s shares opened nearly 3 percent above an offer price that was well below the targeted range.

Google announced on March 24 the latest plans for using smartphones to monitor health, saying the company would test whether capturing heart sounds and eyeball images could help people identify issues from home.

Gemini Therapeutics, a clinical-stage biopharma company dedicated to developing treatments for genetically defined age-related macular degeneration (AMD), announced a series of corporate updates. Among these is a corporate restructuring that will see 80 percent of the company’s workforce laid off.

Shares of Kodiak Sciences plunged in trading on February 23 after the company announced its Phase II/III study of a novel antibody biopolymer conjugate failed to hit the mark in treatment-naïve subjects with neovascular (wet) age-related macular degeneration.

The latest results from Genentech’s proposed eye disease treatments are demonstrating strong potential to help reduce treatment frequencies and deliver improved outcomes.  

The U.S. health regulator approved the first generic version of AbbVie Inc.’s Restasis, a treatment used in increasing tear production in patients with dry-eye syndrome.

The U.S. Food and Drug Administration approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).

Novartis is expanding the company’s position in gene therapy and retinal diseases with the $1.5 billion acquisition of UK-based ocular gene therapy company Gyroscope Therapeutics. 

AbbVie’s Allergan announced that VUITY, the company’s unique treatment for presbyopia, received approval from the U.S. Food and Drug Administration as the first eye drop to be approved for the condition.

The U.S. Food and Drug Administration greenlit Xipere, the first suprachoroidal injectable medicine for macular edema associated with uveitis, co-developed by Clearside Biomedical and Bausch & Lomb.